General MedicationsTOPICALStandard
BRYHALI
HALOBETASOL PROPIONATE
Standard Dose
0.01%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview BRYHALI is listed in Drugs@FDA under application 209355 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient HALOBETASOL PROPIONATE Form and strength LOTION;TOPICAL - 0.01% Sponsor BAUSCH Submission history Latest submission status date: 2018-11-06 00:00:00.
Structured Monograph
Clinical summary
Approval overview BRYHALI is listed in Drugs@FDA under application 209355 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient HALOBETASOL PROPIONATE Form and strength LOTION;TOPICAL - 0.01% Sponsor BAUSCH Submission history Latest submission status date: 2018-11-06 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.